Elena Tsourdi, Matthias Gruber, Martina Rauner, Judith Blankenburg, Tjalf Ziemssen, Lorenz C. Hofbauer
CONTEXT: Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Common adverse effects include an acute-phase reaction, infections and autoimmune diseases, including thyroid disorders …